GH Research PLC (NASDAQ:GHRS - Get Free Report)'s stock price shot up 0.7% during trading on Monday . The company traded as high as $8.38 and last traded at $8.21. 7,879 shares changed hands during trading, a decline of 90% from the average session volume of 79,562 shares. The stock had previously closed at $8.15.
Analyst Ratings Changes
GHRS has been the topic of a number of analyst reports. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th. JMP Securities reissued a "market outperform" rating and issued a $39.00 target price on shares of GH Research in a report on Wednesday, September 4th.
Check Out Our Latest Report on GH Research
GH Research Stock Down 1.8 %
The stock has a market capitalization of $416.22 million, a price-to-earnings ratio of -11.94 and a beta of 0.74. The stock's 50-day simple moving average is $7.96 and its 200 day simple moving average is $10.50.
GH Research (NASDAQ:GHRS - Get Free Report) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03. As a group, equities research analysts anticipate that GH Research PLC will post -0.85 earnings per share for the current year.
Institutional Investors Weigh In On GH Research
A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP lifted its stake in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 19.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,966,726 shares of the company's stock after purchasing an additional 656,163 shares during the period. GH Research makes up about 16.7% of Lynx1 Capital Management LP's investment portfolio, making the stock its 3rd biggest position. Lynx1 Capital Management LP owned approximately 7.62% of GH Research worth $46,252,000 as of its most recent filing with the Securities and Exchange Commission. 56.90% of the stock is owned by institutional investors and hedge funds.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Articles
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
